secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0001724521-24-000096
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARC-9 interim analysis: EZFB combo improves PFS (HR 0.27) and OS (HR 0.37) vs regorafenib in 3L mCRC
--------------------------------------------------------------------------------

- Cohort B (n=112) met primary endpoint: PFS HR 0.27 (p<0.0001), median 6.2 vs 2.1 months.
- OS key secondary: HR 0.37 (p=0.0003), median OS 19.7 vs 9.5 months favoring EZFB.
- ORR 17.3% for EZFB vs 2.7% for regorafenib; safety profile consistent with FOLFOX/bev.
- Data selected for oral presentation at 2024 ASCO Annual Meeting on June 2, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000096/0001724521-24-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000096/rcus-20240523.htm
  HTML page:      https://secwatch.observer/filing/0001724521-24-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer